My Blog

Lengua

Atención al cliente

+123 4567 89

carro $0.00
0
0
Subtotal: $0.00

No products in the cart.

No products in the cart.

Píldoras Libres

con cado pedido

Envío Gratis

sobre todos los pedidos superiores $200

100% De Garantía

de devolución de dinero

Sin Receta

medica

Search by name:

carro $0.00
0
0
Subtotal: $0.00

No products in the cart.

No products in the cart.

Productos

Movfor

Molnupiravir, an Oral Antiviral Treatment for COVID-19
Active Ingredient: Molnupiravir
Availability: In Stock
Exp. Date: Approx. Dec 2025

Ahorre su dinero

Grandes descuentos por los paquestes grandes

Movfor 200mg

ImagePrice200mgQuantityAdd to Cart
$310.8040 caps
$524.4880 caps
$738.15120 caps
$951.83160 caps
$1,165.50200 caps

Product Descripition

Background
Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.

Methods
Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days. Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.

Results
Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.

Conclusions
Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.

Please find the full description of Movfor at Drugs.com and general information at Wikipedia

Scroll to Top